Baudax Bio, Inc. (BXRX)
| Market Cap | 75.05M |
| Revenue (ttm) | 493,000 |
| Net Income (ttm) | -76.10M |
| Shares Out | 70.14M |
| EPS (ttm) | -3.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $1.01 |
| Previous Close | $1.07 |
| Change ($) | -0.06 |
| Change (%) | -5.61% |
| Day's Open | 1.04 |
| Day's Range | 1.01 - 1.07 |
| Day's Volume | 559,150 |
| 52-Week Range | 0.97 - 4.95 |
Investors need to pay close attention to Baudax (BXRX) stock based on the movements in the options market lately.
Annual Meeting to be adjourned solely with respect to Proposal 3 Annual Meeting to be adjourned solely with respect to Proposal 3
MALVERN, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Committe...
Wall Street recommends purchasing shares of Ra Medical Systems Inc (RMED) and Baudax Bio Inc (NASDAQ:BXRX), which sounds quite unexpected since these two equities have shown poor performance over the pr...
MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, President ...
Company Also Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Company Also Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, President ...
Investors need to pay close attention to Baudax Bio (BXRX) stock based on the movements in the options market lately.
MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced ...
MALVERN, Pa., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced ...
Baudax (BXRX) will provide updates on earnings and revenues when it releases results for fourth-quarter 2020.
MALVERN, Pa., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the agreement by an accredited ...
MALVERN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced ...
Investors need to pay close attention to Baudax Bio (BXRX) stock based on the movements in the options market lately.
MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, the Company'...
MALVERN, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced ...
ANJESO Found to Provide Superior Pain Relief with Similar or Better Safety Compared to Other Approved IV Non-Opioid Analgesics ANJESO Found to Provide Superior Pain Relief with Similar or Better Safety ...
Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript
Baudax Bio, Inc.'s (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript
BXRX has been pummeled since the start of the pandemic dropping from the high $7s to the low $1s. In this article, I review the company developments, both negative and positive, that have transpired dur...
MALVERN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it will report third quarte...
ANJESO ® Launch Underway ; Over 50 Institutions have A dded ANJESO to T heir F ormular ies
MALVERN, Pa., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Committee...
MALVERN, Pa., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced Gerri Henwood, the Company’s ...
These penny stocks are company names that won’t break the bank, and boast colossal growth prospects for the 12 months ahead. The post 3 Penny Stocks That Have Triple-Digit Upside Potential appeared fir...
Baudax Bio: Discounted Despite Long-Term Prospects
MALVERN, Pa., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has been awarded a Gro...
MALVERN, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Arnold Baskies, M.D. and ...
Baudax Bio's (BXRX) CEO Gerri Henwood on Q2 2020 Results - Earnings Call Transcript
Commenced Commercial Launch of ANJESO ® in the U.S.
Effective October 1, 2020, New Code Expected to Expand Reimbursement Effective October 1, 2020, New Code Expected to Expand Reimbursement
Virtual Presentation Highlights New ANJESO Clinical Results, Including Safety, Reductions in Opioid Use and Time to Bowel Function Recovery Data When Administered Preoperatively Prior to Colorectal Surg...
MALVERN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has entered into a Pha...
ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily D...
MALVERN, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has closed on a credit...
Baudax Bio, Inc. (BXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
ANJESO™ Approved by FDA for the Management of Moderate to Severe Pain; Product Now Available for Ordering and Delivery for Customers
Virtual Presentation Highlights New ANJESO Health Resource Utilization Data When Administered Preoperatively in Colorectal Surgery as Part of a Multimodal Analgesia Regimen Virtual Presentation Highligh...
Baudax Bio, Inc. (BXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MALVERN, Pa., April 03, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Commit...
MALVERN, Pa., March 26, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced ...
MALVERN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced ...
MALVERN, Pa., March 23, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced ...
Strategic Financing to Provide Funding for the Commercial Launch of ANJESO™ Strategic Financing to Provide Funding for the Commercial Launch of ANJESO™
Tiny, Underfollowed Baudax Bio Way Too Cheap After Receiving FDA Drug Approval
Baudax Bio (BXRX) news for Friday surrounding approval from the U.S. Food & Drug Administration has BXRX stock taking off.
Baudax Bio is a recent spin-out of Recro Pharma's Acute Care Segment and is already preparing for Ajenso's PDUFA date on February 20th.
PDUFA Goal Date Set for February 20, 2020 PDUFA Goal Date Set for February 20, 2020
About BXRX
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial,... [Read more...]
| Industry Biotechnology | |
| Stock Exchange NASDAQ | Ticker Symbol BXRX |
Analyst Forecasts
According to 3 analysts, the average rating for Baudax Bio stock is "Buy." The 12-month stock price forecast is 4.67, which is an increase of 362.38% from the latest price.